FDA CLEAREDgammaCore™ (nVNS), an electroCore product, is now indicated for adjunctive use for the preventive treatment of cluster headache. Learn More Toggle navigation Select Language English German Italian Home About Us Leadership Culture of Innovation Our History Patient Advocacy & Support nVNS Therapy Product Developments Therapeutic Areas Pipeline For Payers Careers Investors News Releases Events and Presentations Corporate Governance SEC Filings Investor Services News Media Kit Contact Us
Initial Public Offering Posted on June 14, 2018, updated on June 14, 2018 by electrocore_admin In June 2018, we announced an IPO with the Nasdaq Global Select Market and began trading under ECOR. Go Back